Drug Profile
Research programme: Gaucher's disease therapy - BioDelivery Sciences
Alternative Names: Biorazyme; Gaucher's disease therapy research programme - BioDelivery ScienceLatest Information Update: 24 Mar 2022
Price :
$50
*
At a glance
- Originator BioDelivery Sciences International
- Class
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gaucher's disease
Most Recent Events
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 09 Dec 2004 Preclinical trials in Gaucher's disease in USA (PO)